Royal Bank Of Canada Forecasts Strong Price Appreciation for MannKind (NASDAQ:MNKD) Stock

MannKind (NASDAQ:MNKD) had its price target hoisted by stock analysts at Royal Bank Of Canada from $4.75 to $5.00 in a report issued on Friday, Benzinga reports. The brokerage currently has a “sector perform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada‘s target price points to a potential upside of 28.37% from the stock’s current price.

A number of other equities research analysts also recently weighed in on the company. Wells Fargo & Company lowered their target price on MannKind from $14.00 to $13.00 and set an “overweight” rating for the company in a report on Thursday, August 6th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of MannKind in a research note on Friday, October 2nd. Chardan Capital assumed coverage on shares of MannKind in a report on Monday, October 19th. They set a “buy” rating and a $10.00 price objective on the stock. Wall Street Zen cut shares of MannKind from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Finally, Truist Financial reduced their target price on MannKind from $6.00 to $5.00 and set a “buy” rating for the company in a research note on Wednesday, October 7th. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $8.33.

MannKind Trading Up 3.6%

NASDAQ:MNKD traded up $0.14 during mid-day trading on Friday, hitting $3.90. 2,294,307 shares of the company’s stock were exchanged, compared to its average volume of 5,096,323. The company has a 50 day simple moving average of $3.55 and a 200-day simple moving average of $3.72. MannKind has a fifty-two week low of $2.23 and a fifty-two week high of $6.51. The firm has a market capitalization of $1.25 billion, a P/E ratio of -29.96 and a beta of 1.10.

MannKind (NASDAQ:MNKD) last issued its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.05. The business had revenue of $101.87 million during the quarter, compared to the consensus estimate of $107.74 million. The business’s revenue for the quarter was up 24.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.03 EPS. As a group, analysts expect that MannKind will post -0.21 earnings per share for the current year.

Insider Transactions at MannKind

In other MannKind news, Director Steven Binder sold 39,051 shares of the business’s stock in a transaction that occurred on Friday, September 25th. The stock was sold at an average price of $3.29, for a total transaction of $128,477.79. Following the completion of the sale, the director directly owned 713,258 shares of the company’s stock, valued at approximately $2,346,618.82. The trade was a 5.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 2.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Waverly Advisors LLC grew its holdings in MannKind by 43.0% during the second quarter. Waverly Advisors LLC now owns 24,948 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 7,498 shares in the last quarter. Chicago Partners Investment Group LLC raised its position in MannKind by 22.1% in the 1st quarter. Chicago Partners Investment Group LLC now owns 42,691 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 7,741 shares during the last quarter. Sterling Capital Management LLC lifted its stake in MannKind by 864.1% during the 3rd quarter. Sterling Capital Management LLC now owns 10,422 shares of the biopharmaceutical company’s stock valued at $41,000 after acquiring an additional 9,341 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in MannKind by 15.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 71,469 shares of the biopharmaceutical company’s stock valued at $279,000 after acquiring an additional 9,799 shares in the last quarter. Finally, Royal Bank of Canada lifted its stake in MannKind by 4.8% during the 1st quarter. Royal Bank of Canada now owns 216,563 shares of the biopharmaceutical company’s stock valued at $531,000 after acquiring an additional 9,951 shares in the last quarter. Hedge funds and other institutional investors own 49.55% of the company’s stock.

Key Headlines Impacting MannKind

Here are the key news stories impacting MannKind this week:

• Positive Sentiment: Cantor Fitzgerald raised its price target to $10 from $8 and reiterated an “overweight” rating, signaling confidence in MannKind’s prospects. Cantor Fitzgerald analyst ratings
• Positive Sentiment: MannKind said it anticipates about $1 billion in revenue from its United Therapeutics deal during 2027–2030 and is targeting profitability in the fourth quarter. This outlook could support investor expectations for future growth. MannKind’s United Therapeutics outlook
• Positive Sentiment: Third-quarter revenue grew 24% year over year, and the reported loss per share was narrower than analysts expected, offering some positive signals on operating performance. MannKind third-quarter results and business update
• Negative Sentiment: Revenue of $101.87 million missed the $107.74 million consensus estimate. MannKind also reported a quarterly loss, compared with earnings in the year-ago quarter, underscoring that profitability remains a challenge. MannKind reports third-quarter loss and revenue miss

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).